最近胶质母细胞瘤的多模态治疗进展。
Recent advancements in multimodality treatment of gliomas.
机构信息
Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center & Richard L Solove Research Institute, The Ohio State University Medical Center, Columbus, 43210, USA.
出版信息
Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102.
Abstract
Gliomas account for the vast majority of malignant adult brain tumors. Even though tremendous effort has been made to optimize treatment of patients with high-grade glioma, the prognosis remains poor, especially for patients with glioblastoma. The dismal prognosis conferred by these tumors is in part caused by the tendency to diffusely infiltrate into neighboring brain tissue, but also by the inherent resistance of these tumors to both chemotherapy and radiation. This article reviews the recent advancements in multimodality treatment of patients with gliomas, both in the primary and recurrent setting, with an emphasis on the emerging targeted therapies. Moreover, the external beam radiotherapy options, including intensity modulated radiotherapy and particle (proton and carbon ion) radiotherapy are reviewed.
摘要
神经胶质瘤占成人脑肿瘤的绝大多数。尽管为优化高级别神经胶质瘤患者的治疗做出了巨大努力，但预后仍然不佳，尤其是胶质母细胞瘤患者。这些肿瘤带来的不良预后部分是由于它们向邻近脑组织弥漫性浸润的倾向，也部分是由于这些肿瘤对化疗和放疗的固有耐药性。本文综述了在原发性和复发性脑胶质瘤患者的多模态治疗方面的最新进展，重点介绍了新兴的靶向治疗。此外，还回顾了外照射放疗的选择，包括调强放疗和粒子（质子和碳离子）放疗。
相似文献
1
Recent advancements in multimodality treatment of gliomas.最近胶质母细胞瘤的多模态治疗进展。
Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102.
2
Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.了解高级别胶质瘤：分子机制、治疗和综合管理。
Cancer Lett. 2013 May 1;331(2):139-46. doi: 10.1016/j.canlet.2012.12.024. Epub 2013 Jan 20.
3
[Treatment modalities for malignant gliomas with reference to their pathophysiology].[参照恶性胶质瘤病理生理学的治疗方式]
Gan To Kagaku Ryoho. 1986 Jan;13(1):11-7.
4
Management of diffuse glioma.弥漫性胶质瘤的管理
Presse Med. 2018 Nov-Dec;47(11-12 Pt 2):e199-e212. doi: 10.1016/j.lpm.2018.04.014. Epub 2018 Oct 29.
5
[Controversy on treatments for gliomas].[胶质瘤治疗的争议]
Gan To Kagaku Ryoho. 1998 Sep;25(11):1650-6.
6
[Management of gliomas].[胶质瘤的管理]
Cancer Radiother. 2014 Oct;18(5-6):461-7. doi: 10.1016/j.canrad.2014.07.147. Epub 2014 Sep 4.
7
Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.神经外科医师大会关于复发性弥漫性低级别胶质瘤管理的系统评价和循证指南：更新版
J Neurooncol. 2025 Jan;171(1):105-130. doi: 10.1007/s11060-024-04838-5. Epub 2024 Oct 14.
8
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.颅内增强递送卡铂治疗复发性高级别胶质瘤的 I 期试验。
PLoS One. 2020 Dec 29;15(12):e0244383. doi: 10.1371/journal.pone.0244383. eCollection 2020.
9
Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.弥漫性脑桥胶质瘤的治疗策略：超分割放疗和化疗的治疗作用
J Neurooncol. 1996 May-Jun;28(2-3):207-22. doi: 10.1007/BF00250200.
10
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.恶性胶质瘤的多模态治疗。几种辅助治疗方法的比较。
Zentralbl Neurochir. 1981;42(2-3):99-119.
引用本文的文献
1
Identification and Validation of Prognostic Genes Related to Histone Lactylation Modification in Glioblastoma: An Integrated Analysis of Transcriptome and Single-cell RNA Sequencing.胶质母细胞瘤中与组蛋白乳酸化修饰相关的预后基因的鉴定与验证：转录组和单细胞RNA测序的综合分析
J Cancer. 2025 Mar 21;16(7):2145-2166. doi: 10.7150/jca.110646. eCollection 2025.
2
The pathogenesis mechanism and potential clinical value of lncRNA in gliomas.lncRNA在胶质瘤中的发病机制及潜在临床价值
Discov Oncol. 2024 Jul 5;15(1):266. doi: 10.1007/s12672-024-01144-4.
3
CDCA3 is a potential biomarker for glioma malignancy and targeted therapy.CDCA3 是一种潜在的脑胶质瘤恶性肿瘤和靶向治疗的生物标志物。
Medicine (Baltimore). 2024 May 10;103(19):e38066. doi: 10.1097/MD.0000000000038066.
4
Establishment of a 3D Model to Characterize the Radioresponse of Patient-Derived Glioblastoma Cells.建立用于表征患者来源的胶质母细胞瘤细胞放射反应的三维模型。
Cancers (Basel). 2023 Aug 10;15(16):4051. doi: 10.3390/cancers15164051.
5
High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas.EZH2蛋白高表达是IDH1 R132H阴性胶质瘤预后不良的预测指标。
Diagnostics (Basel). 2022 Sep 30;12(10):2383. doi: 10.3390/diagnostics12102383.
6
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.替莫唑胺联合或不联合尼莫妥珠单抗放化疗治疗新诊断的 EGFR 阳性胶质母细胞瘤的回顾性队列研究。
Oncologist. 2023 Jan 18;28(1):e45-e53. doi: 10.1093/oncolo/oyac202.
7
Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.基于纳米颗粒的胶质母细胞瘤放射增敏的新策略。
Int J Mol Sci. 2021 Sep 7;22(18):9673. doi: 10.3390/ijms22189673.
8
Cannabidiol Induces Apoptosis and Perturbs Mitochondrial Function in Human and Canine Glioma Cells.大麻二酚诱导人和犬神经胶质瘤细胞凋亡并扰乱线粒体功能。
Front Pharmacol. 2021 Aug 11;12:725136. doi: 10.3389/fphar.2021.725136. eCollection 2021.
9
Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival.O6-甲基鸟嘌呤-DNA甲基转移酶在胶质瘤中的免疫组化表达及其在确定患者生存情况中的作用。
Med Pharm Rep. 2021 Jul;94(3):318-324. doi: 10.15386/mpr-1951. Epub 2021 Jul 29.
10
Ischemic Stroke After Tumor Resection in a Patient With Glioblastoma Multiforme.多形性胶质母细胞瘤患者肿瘤切除术后的缺血性卒中
Cureus. 2021 Feb 8;13(2):e13232. doi: 10.7759/cureus.13232.
本文引用的文献
1
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.CT-322（一种基于人纤连蛋白结构域的VEGFR-2靶向生物抑制剂）用于复发性胶质母细胞瘤的2期研究。
Invest New Drugs. 2015 Feb;33(1):247-53. doi: 10.1007/s10637-014-0186-2. Epub 2014 Nov 13.
2
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.立体定向放射外科和辅助贝伐单抗治疗复发性恶性脑胶质瘤的安全性和有效性。
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.
3
Imaging of tumor physiology: impacts on clinical radiation oncology.肿瘤生理学成像：对临床放射肿瘤学的影响。
Exp Oncol. 2010 Sep;32(3):149-52.
4
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.贝伐珠单抗联合替莫唑胺在新诊断的多形性胶质母细胞瘤患者放疗期间和放疗后的 II 期研究。
J Clin Oncol. 2011 Jan 10;29(2):142-8. doi: 10.1200/JCO.2010.30.2729. Epub 2010 Dec 6.
5
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.表皮生长因子受体变异 III 肽疫苗接种延长无进展生存期后新诊断胶质母细胞瘤患者的免疫逃逸。
J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.
6
Molecular diagnostics of gliomas: the clinical perspective.脑胶质瘤的分子诊断：临床视角。
Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23.
7
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.随机 II 期研究评估了在替莫唑胺联合放化疗后应用碳离子推量与在替莫唑胺放化疗后应用质子推量治疗原发性胶质母细胞瘤患者的疗效：CLEOPATRA 试验。
BMC Cancer. 2010 Sep 6;10:478. doi: 10.1186/1471-2407-10-478.
8
PET for radiation treatment planning of brain tumours.正电子发射断层扫描（PET）在脑肿瘤放射治疗计划中的应用。
Radiother Oncol. 2010 Sep;96(3):325-7. doi: 10.1016/j.radonc.2010.08.001. Epub 2010 Aug 20.
9
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.多形性胶质母细胞瘤患者一线治疗中同步放化疗联合替莫唑胺序贯替莫唑胺和索拉非尼。
Cancer. 2010 Aug 1;116(15):3663-9. doi: 10.1002/cncr.25275.
10
Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS).碳离子放疗：国立放射科学研究所（NIRS）的临床经验。
J Radiat Res. 2010;51(4):355-64. doi: 10.1269/jrr.10016. Epub 2010 May 28.
Zotero 插件